ONtrack Biomedical AG

ONtrack Biomedical AG is a UZH MedTech company that develops in-vitro diagnostic tests for the non-invasive early detection and monitoring of cancer.

The first product in the pipeline is called PROBAN, a urine test that facilitates the early detection of prostate cancer. The aim is to spare men an unnecessary prostate biopsy due to unspecifically high serum PSA levels.

At the same time, the test could be used more often due to lower costs to ensure that those men who have a prostate tumor do not miss the chance of early detection.

As a non-invasive test, it can serve as an eligibility criterion before a prostate biopsy to reduce the burden on patients and the healthcare system.

ONtrack Biomedical's PROBAN is currently in development to detect patients at risk for a specific prostate tumor.